Imunon Reports Promising Phase 2 Ovarian Cancer Trial Results
Company Announcements

Imunon Reports Promising Phase 2 Ovarian Cancer Trial Results

Imunon (IMNN) has provided an announcement.

Imunon, Inc. has revealed encouraging results from its Phase 2 OVATION 2 trial, which tested IMNN-001 alongside standard chemotherapy treatments for advanced ovarian cancer. The data indicates that the treatment could potentially extend the median time to event and improve overall survival rates, although statistical significance was not reached. Investors and interested parties are invited to a conference call and can access more information via a webcast or the investor presentation on the company’s website.

For an in-depth examination of IMNN stock, go to TipRanks’ Stock Analysis page.

Related Articles
Brian AndersonImunon, Inc. (IMNN) Q3 Earnings Cheat Sheet
TheFlyImunon to present Phase 2 data of IMNN-001
TheFlyImunon reports inducement grant under NASDAQ listing rule
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App